Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Abstract Background CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) are approved for the treatment of ER+ advanced breast cancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. We previously reported a novel therapeutic agent, ERX-11, that binds to the...

Descripció completa

Dades bibliogràfiques

Autors principals:	Suryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, Tae-Kyung Lee, Mengxing Li, Collin Gilbreath, Xihui Liu, Yiliao Luo, Uday P. Pratap, Mei Zhou, Eliot B. Blatt, Kara Kassees, Carlos Arteaga, Prasanna Alluri, Manjeet Rao, Susan T. Weintraub, Rajeshwar Rao Tekmal, Jung-Mo Ahn, Ganesh V. Raj, Ratna K. Vadlamudi
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-12-01
Col·lecció:	Breast Cancer Research
Matèries:	Estrogen receptor (ER) ER coregulators Breast cancer ER coregulator modulator Therapy-resistant breast cancer CDK4/6 inhibitor
Accés en línia:	https://doi.org/10.1186/s13058-019-1227-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!